Histamine H2 receptor-mediated suppression of intestinal inflammation by probiotic lactobacillus reuteri

mBio

Volumn 6, Issue 6, 2015, Pages

  Gao, Chunxu ^a,b   Major, Angela ^b   Rendon, David ^a   Lugo, Monica ^a,b   Jackson, Vanessa ^a,b   Shi, Zhongcheng ^a,b   Mori Akiyama, Yuko ^a,b   Versalovic, James ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; HISTAMINE H2 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROBIOTIC AGENT; SERUM AMYLOID A; TRINITROBENZENESULFONIC ACID; HISTAMINE; HISTIDINE; HISTIDINE DECARBOXYLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; COLITIS; COLON INJURY; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; GENE CLUSTER; GENE EXPRESSION; HDC GENE; IMMUNOMODULATION; IN VIVO STUDY; INTESTINE FLORA; LACTOBACILLUS REUTERI; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; ANIMAL; CHEMICALLY INDUCED; COLON; DIET; DISEASE MODEL; ENZYMOLOGY; GENETICS; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; COLITIS; COLON; DIET; DISEASE MODELS, ANIMAL; GASTROINTESTINAL MICROBIOME; HISTAMINE; HISTIDINE; HISTIDINE DECARBOXYLASE; IMMUNOMODULATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTESTINAL MUCOSA; LACTOBACILLUS REUTERI; MICE; POSITRON-EMISSION TOMOGRAPHY; PROBIOTICS; RECEPTORS, HISTAMINE H2; SERUM AMYLOID A PROTEIN; SIGNAL TRANSDUCTION; TRINITROBENZENESULFONIC ACID;

EID: 84952836854     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01358-15     Document Type: Article

References (51)

1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. 2012. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142:46-54. http://dx.doi.org/10.1053/j.gastro.2011.10.001.
2. Moradkhani A, Beckman LJ, Tabibian JH. 2013. Health-related quality of life in inflammatory bowel disease: psychosocial, clinical, socioeconomic, and demographic predictors. J Crohns Colitis 7:467-473. http:// dx.doi.org/10.1016/j.crohns.2012.07.012.
3. Benchimol EI, To T, Griffiths AM, Rabeneck L, Guttmann A. 2011. Outcomes of pediatric inflammatory bowel disease: socioeconomic status disparity in a universal-access healthcare system. J Pediatr 158:960-967. http://dx.doi.org/10.1016/j.jpeds.2010.11.039.
4. Knights D, Lassen KG, Xavier RJ. 2013. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 62: 1505-1510. http://dx.doi.org/10.1136/gutjnl-2012-303954.
5. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottiere HM, Dore J, Marteau P, Seksik P, Langella P. 2008. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105:16731-16736. http://dx.doi.org/10.1073/pnas.0804812105.
6. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. 2000. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119:305-309. http:// dx.doi.org/10.1053/gast.2000.9370.
7. Casas IA, Dobrogosz WJ. 2000. Validation of the probiotic concept: Lactobacillus reuteri confers broad-spectrum protection against disease in humans and animals. Microb Ecol Health Dis 12:247-285. http:// dx.doi.org/10.1080/08910600050216246-1.
8. Liu Y, Fatheree NY, Mangalat N, Rhoads JM. 2010. Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 299:G1087-G1096. http://dx.doi.org/10.1152/ajpgi.00124.2010.
9. Thomas CM, Hong T, van Pijkeren JP, Hemarajata P, Trinh DV, Hu W, Britton RA, Kalkum M, Versalovic J. 2012. Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling. PLoS One 7:e31951. http://dx.doi.org/10.1371/ journal.pone.0031951.
10. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. 1999. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 116:1107-1114. http://dx.doi.org/10.1016/S0016-5085(99)70013-2.
11. Pena JA, Li SY, Wilson PH, Thibodeau SA, Szary AJ, Versalovic J. 2004. Genotypic and phenotypic studies of murine intestinal lactobacilli: species differences in mice with and without colitis. Appl Environ Microbiol 70: 558-568. http://dx.doi.org/10.1128/AEM.70.1.558-568.2004.
12. Schreiber O, Petersson J, Phillipson M, Perry M, Roos S, Holm L. 2009. Lactobacillus reuteri prevents colitis by reducing P-selectin-associated leukocyte-and platelet-endothelial cell interactions. Am J Physiol Gastrointest Liver Physiol 296:G534-G542. http://dx.doi.org/10.1152/ ajpgi.90470.2008.
13. Preidis GA, Saulnier DM, Blutt SE, Mistretta T, Riehle KP, Major AM, Venable SF, Barrish JP, Finegold MJ, Petrosino JF, Guerrant RL, Conner ME, Versalovic J. 2012. Host response to probiotics determined by nutritional status of rotavirus-infected neonatal mice. J Pediatr Gastroenterol Nutr 55:299-3 0 7. http://dx.doi. org/1 0. 1 0 9 7 / MPG.0b013e31824d2548.
14. Spinler JK, Sontakke A, Hollister EB, Venable SF, Oh PL, Balderas MA, Saulnier DMA, Mistretta TA, Devaraj S, Walter J, Versalovic J, Highlander SK. 2014. From prediction to function using evolutionary genomics: human-specific ecotypes of Lactobacillus reuteri have diverse probiotic functions. Genome Biol Evol 6:1772-1789. http://dx.doi.org/ 10.1093/gbe/evu137.
15. Preidis GA, Versalovic J. 2009. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 136:2015-2031. http://dx.doi.org/ 10.1053/j.gastro.2009.01.072.
16. Hemarajata P, Gao C, Pflughoeft KJ, Thomas CM, Saulnier DM, Spinler JK, Versalovic J. 2013. Lactobacillus reuteri-specific immunoregulatory gene rsiR modulates histamine production and immunomodulation by Lactobacillus reuteri. J Bacteriol 195:5567-5576. http://dx.doi.org/ 10.1128/JB.00261-13.
17. Scheiffele F, Fuss IJ. 2002. Induction of TNBS colitis in mice. Curr Protoc Immunol Chapter 15:Unit 15.19. http://dx.doi.org/10.1002/ 0471142735.im1519s49.
18. Wallace JL, MacNaughton WK, Morris GP, Beck PL. 1989. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96:29-36.
19. Foligné B, Nutten S, Steidler L, Dennin V, Goudercourt D, Mercenier A, Pot B. 2006. Recommendations for improved use of the murine TNBSinduced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: technical and microbiological aspects. Dig Dis Sci 51: 390-400. http://dx.doi.org/10.1007/s10620-006-3143-x.
20. Ameho CK, Adjei AA, Harrison EK, Takeshita K, Morioka T, Arakaki Y, Ito E, Suzuki I, Kulkarni AD, Kawajiri A, Yamamoto S. 1997. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut 41:487-493. http://dx.doi.org/10.1136/ gut.41.4.487.
21. De Villiers WJS, Varilek GW, de Beer FC, Guo J, Kindy MS. 2000. Increased serum amyloid a levels reflect colitis severity and precede amyloid formation in IL-2 knockout mice. Cytokine 12:1337-1347. http:// dx.doi.org/10.1006/cyto.2000.0716.
22. Sasaoka T, Ito M, Yamashita J, Nakajima K, Tanaka I, Narita M, Hara Y, Hada K, Takahashi M, Ohno Y, Matsuo T, Kaneshiro Y, Tanaka H, Kaneko K. 2011. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Am J Physiol Gastrointest Liver Physiol 300:G568-G576. http:// dx.doi.org/10.1152/ajpgi.00329.2010.
23. Dutra RC, Claudino RF, Bento AF, Marcon R, Schmidt EC, Bouzon ZL, Pianowski LF, Calixto JB. 2011. Preventive and therapeutic euphol treatment attenuates experimental colitis in mice. PLoS One 6:e27122. http:// dx.doi.org/10.1371/journal.pone.0027122.
24. Brewer S, McPherson M, Fujiwara D, Turovskaya O, Ziring D, Chen L, Takedatsu H, Targan SR, Wei B, Braun J. 2008. Molecular imaging of murine intestinal inflammation with 2-deoxy-2-[18F]fluoro-D-glucose and positron emission tomography. Gastroenterology 135:744-755. http://dx.doi.org/10.1053/j.gastro.2008.06.040.
25. Galitovskiy V, Kuruvilla S, Sevriokov E, Corches A, Pan M, Kalantari-Dehaghi M, Chernyavsky A, Mukherjee J, Grando S. 2013. Development of novel approach to diagnostic imaging of lung cancer with 18F-Nifene PET/CT using A/J mice treated with NNK. J Cancer Res Ther 1:128-137. http://dx.doi.org/10.14312/2052-4994.2013-20.
26. Shibata K, Fukuwatari T, Zushi S, Sugimoto E. 2001. Effect of dietary histidine content on the change in content of skin urocanic acid isomers in hairless mice irradiated with ultraviolet B. Biosci Biotechnol Biochem 65: 1415-1418. http://dx.doi.org/10.1271/bbb.65.1415.
27. O'Mahony L, Akdis M, Akdis CA. 2011. Regulation of the immune response and inflammation by histamine and histamine receptors. J Allergy Clin Immunol 128:1153-1162. http://dx.doi.org/10.1016/ j.jaci.2011.06.051.
28. Sander LE, Lorentz A, Sellge G, Coeffier M, Neipp M, Veres T, Frieling T, Meier PN, Manns MP, Bischoff SC. 2006. Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract. Gut 55:498-504.
29. Kim H, Dwyer L, Song JH, Martin-Cano FE, Bahney J, Peri L, Britton FC, Sanders KM, Koh SD. 2011. Identification of histamine receptors and effects of histamine on murine and simian colonic excitability. Neurogastroenterol Motil 23:949-e409. http://dx.doi.org/10.1111/j.1365-2982.2011.01760.x.
30. Jutel M, Watanabe T, Klunker S, Akdis M, Thomet OAR, Malolepszy J, Zak-Nejmark T, Koga R, Kobayashi T, Blaser K, Akdis CA. 2001. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 413:420-425. http://dx.doi.org/ 10.1038/35096564.
31. Frei R, Ferstl R, Konieczna P, Ziegler M, Simon T, Rugeles TM, Mailand S, Watanabe T, Lauener R, Akdis CA, O'Mahony L. 2013. Histamine receptor 2 modifies dendritic cell responses to microbial ligands. J Allergy Clin Immunol 132:194-204. http://dx.doi.org/10.1016/ j.jaci.2013.01.013.
32. Funaki C, Hodges RR, Dartt DA. 2010. Identification of the Raf-1 signaling pathway used by cAMP to inhibit p42/p44 MAPK in rat lacrimal gland acini: role in potentiation of protein secretion. Invest Ophthalmol Vis Sci 51:6321-6328. http://dx.doi.org/10.1167/iovs.10-5690.
33. Hershenson MB, Chao TS, Abe MK, Gomes I, Kelleher MD, Solway J, Rosner MR. 1995. Histamine antagonizes serotonin and growth factorinduced mitogen-activated protein kinase activation in bovine tracheal smooth muscle cells. J Biol Chem 270:19908-19913. http://dx.doi.org/ 10.1074/jbc.270.34.19908.
34. Waltereit R, Weller M. 2003. Signaling from cAMP/PKA to MAPK and synaptic plasticity. Mol Neurobiol 27:99-106. http://dx.doi.org/10.1385/ MN:27:1:99.
35. Garnett WR. 2003. History of acid suppression: focus on the hospital setting. Pharmacotherapy 23:56S-60S. http://dx.doi.org/10.1592/ phco.23.13.56S.31932.
36. Elenkov IJ, Webster E, Papanicolaou DA, Fleisher TA, Chrousos GP, Wilder RL. 1998. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J Immunol 161:2586-2593.
37. Horvath B, Szalai C, Mandi Y, Laszlo V, Radvany Z, Darvas Z, Falus A. 1999. Histamine and histamine-receptor antagonists modify gene expression and biosynthesis of interferon gamma in peripheral human blood mononuclear cells and in CD19-depleted cell subsets. Immunol Lett 70: 95-99. http://dx.doi.org/10.1016/S0165-2478(99)00126-1.
38. Bissonnette EY. 1996. Histamine inhibits tumor necrosis factor alpha release by mast cells through H2 and H3 receptors. Am J Respir Cell Mol Biol 14:620-626. http://dx.doi.org/10.1165/ajrcmb.14.6.8652190.
39. Mazzoni A, Young HA, Spitzer JH, Visintin A, Segal DM. 2001. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest 108:1865-1873. http:// dx.doi.org/10.1172/JCI200113930.
40. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C. 2012. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 13:R79. http://dx.doi.org/10.1186/gb-2012-13-9-r79.
41. Gupta RW, Tran L, Norori J, Ferris MJ, Eren AM, Taylor CM, Dowd SE, Penn D. 2013. Histamine-2 receptor blockers alter the fecal microbiota in premature infants. J Pediatr Gastroenterol Nutr 56:397-400. http:// dx.doi.org/10.1097/MPG.0b013e318282a8c2.
42. Terrin G, Passariello A, De Curtis M, Manguso F, Salvia G, Lega L, Messina F, Paludetto R, Canani RB. 2012. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics 129:e40-e45. http://dx.doi.org/10.1542/peds.2011-0796.
43. Guillet R, Stoll BJ, Cotten CM, Gantz M, McDonald S, Poole WK, Phelps DL. 2006. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 117:e137-e142. http://dx.doi.org/10.1542/peds.2005-1543.
44. Juillerat P, Schneeweiss S, Cook EF, Ananthakrishnan AN, Mogun H, Korzenik JR. 2012. Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease. Aliment Pharmacol Ther 36: 239-247. http://dx.doi.org/10.1111/j.1365-2036.2012.05173.x.
45. Akdis CA, Blaser K. 2003. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 112:15-22. http://dx.doi.org/ 10.1067/mai.2003.1585.
46. Van Pijkeren JP, Britton RA. 2012. High efficiency recombineering in lactic acid bacteria. Nucleic Acids Res 40:e76. http://dx.doi.org/10.1093/ nar/gks147.
47. Togias A. 2003. H1-receptors: localization and role in airway physiology and in immune functions. J Allergy Clin Immunol 112:S60-S68. http:// dx.doi.org/10.1016/S0091-6749(03)01878-5.
48. Naila A, Flint S, Fletcher G, Bremer P, Meerdink G. 2010. Control of biogenic amines in food-existing and emerging approaches. J Food Sci 75:R139-R150. http://dx.doi.org/10.1111/j.1750-3841.2010.01774.x.
49. Thurmond RL, Gelfand EW, Dunford PJ. 2008. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 7:41-53. http://dx.doi.org/10.1038/nrd2465.
50. Li H, Cao Y. 2010. Lactic acid bacterial cell factories for gammaaminobutyric acid. Amino Acids 39:1107-1116. http://dx.doi.org/ 10.1007/s00726-010-0582-7.
51. Marcobal A, De las Rivas B, Landete JM, Tabera L, Muñoz R. 2012. Tyramine and phenylethylamine biosynthesis by food bacteria. Crit Rev Food Sci Nutr 52:448-467. http://dx.doi. org/1 0. 1 0 8 0 / 10408398.2010.500545.